Dyslipidemia resident survival guide: Difference between revisions
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
Line 139: | Line 139: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | A01 | | | | | | | | | | | | | | | |A01='''Obtain a detailed history'''<br><br>'''''History of present illness'''''<br> | {{familytree | | | | | | | | | | | A01 | | | | | | | | | | | | | | | |A01='''Obtain a detailed history'''<br><br><div style="float: left; text-align: left; width: 18em; padding:1em;">'''''History of present illness'''''<br> | ||
❑ Address specific patient symptoms and complaints<br> | ❑ Address specific patient symptoms and complaints<br> | ||
Line 244: | Line 244: | ||
❑ Stress<br> | ❑ Stress<br> | ||
❑ Sexual lifestyle & contraceptive methods <br> | ❑ Sexual lifestyle & contraceptive methods <br></div>}} | ||
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | | | B01 | | | | | | | | | | | | | | | |B01='''Assess for CAD risk factors'''<br><br><div style="float: left; text-align: left; width: 18em; padding:1em;">'''''Major risk factors:'''''<br> | |||
❑ Advanced age <br> | |||
❑ ↑ total serum cholesterol <br> | |||
❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C)<br> | |||
❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5))<br> | |||
❑ ↓ HDL-C<br> | |||
❑ Diabetes mellitus<br> | |||
❑ Hypertension<br> | |||
❑ Cigarette smoking<br> | |||
❑ Family history of CAD<br><br> | |||
'''''Additional risk factors:'''''<br> | |||
❑ Obesity, especially abdominal<br> | |||
❑ Family history of hyperlipidemia<br> | |||
❑ Small, dense LDL-C<br> | |||
❑ ↑ Apo-B<br> | |||
❑ ↑ LDL particle number (measured by ApoB)<br> | |||
❑ Fasting/postprandial hypertriglyceridemia<br> | |||
❑ Polycystic ovarian syndrome<br> | |||
❑ Dyslipidemic triad<br><br> | |||
'''''Non-traditional risk factors:'''''<br> | |||
❑ ↑ lipoprotein<br> | |||
❑ ↑ clotting factors<br> | |||
❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2)<br> | |||
❑ Hyperhomocysteinemia<br> | |||
❑ ApoE4 isoform<br> | |||
❑ ↑ uric acid</div> | |||
}} | }} | ||
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | C01 | | | | | | | | | | | | | | | |C01='''Screen for possible common causes of secondary dyslipidemia'''<br> | |||
Hypothyroidism: Order TSH, FT4, and FT3 | |||
{{familytree | | | | | | | | | | | C01 | | | | | | | | | | | | | | | |C01='''Screen for possible causes of secondary dyslipidemia'''<br>}} | Nephrosis: Order serum creatinine and urinalysis with either spot urine for proteins or 24-hour urinary collection for proteins, urinary protein to creatinine ratio | ||
Dysgammaglobulinemia: Order ANA, anti-dsDNA antibodies, plasma and urine electrophoresis | |||
Cholestatic hepatic diseases: Order GGT, ALP, and bilirubins | |||
Chronic kidney disease: Order serum creatinine, BUN, urinalysis, and renal ultrasound | |||
Type 2 diabetes mellitus: Order glycemia and HbA1c | |||
Excessive alcohol intake | |||
Drugs (estrogen, progestin, protease inhibitors, beta-blockers, corticosteroids, anabolic steroids) | |||
}} | |||
{{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | C02 | | | | | | | | | | | | | | | |C02=Evaluate the patient's 10-year global risk of CAD}} | {{familytree | | | | | | | | | | | C02 | | | | | | | | | | | | | | | |C02=Evaluate the patient's 10-year global risk of CAD}} |
Revision as of 18:10, 20 April 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Classification
Causes
Secondary causes of dyslipidemia may cause either an increase in total-cholesterol & low density lipoprotein-cholesterol (LDL-C) or an increase in total triglycerides & very low density lipoprotein cholesterol (VLDL-C). Common causes are listed below.
Increase in Total Cholesterol and LDL-C
- Hypothyroidism
- Nephrosis
- Dysgammaglobulinemia (systemic lupus erythematosus, multiple myeloma)
- Cholestatic hepatic diseases due to abnormal lipoproteins (e.g. primary biliary cirrhosis)
- Administration of protease inhibitors (treatment for HIV infection)
- Administration of progestin or anabolic steroids
Increase in Total Triglycerides and VLDL-C
- Chronic kidney disease
- Type 2 diabetes mellitus
- Obesity
- Excessive alcohol intake
- Hypothyroidism
- Administration of anti-hypertensive therapy (thiazide diuretics or B-blockers)
- Administration of corticosteroids
- Severe stress that increases endogenous corticosteroid concentration
- Elevated concentrations of estrogen (administration of oral (not transdermal) estrogen therapy, oral contraceptives, or pregnancy)
- Administration of protease inhibitors (treatment for HIV infection)
To view a comprehensive list of dyslipidemia causes, click here
Screening
Abbreviations: ASA: American society of anesthesiologists; BP: Blood Pressure; CCS: Canadian cardiovascular society; CrCl: Creatinine clearance; CXR: Chest X-ray; DNI: Do not intubate; DNR: Do not resuscitate; ECG: Electrocardiogram; eGFR: estimated glomerular filtration rate; HR:Heart rate; INR: International normalized ratio; LMWH: Low molecular weight heparin; LV: Left ventricle; LVED: Left ventricular ejection fraction; NOAC: Novel oral anticoagulant; NPO: Nothing per os; PMI: Point of maximal impulse; PT: Prothrombin time; RR: Respiratory rate; SpO2: Oxygen saturation; T: Temperature; VT: Ventricular tachycardia
Identify risk factors for CAD Major risk factors: ❑ Advanced age ❑ ↑ total serum cholesterol ❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C) ❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5)) ❑ ↓ HDL-C ❑ Diabetes mellitus ❑ Hypertension ❑ Cigarette smoking ❑ Family history of CAD ❑ Obesity, especially abdominal ❑ Family history of hyperlipidemia ❑ Small, dense LDL-C ❑ ↑ Apo-B ❑ ↑ LDL particle number (measured by ApoB) ❑ Fasting/postprandial hypertriglyceridemia ❑ Polycystic ovarian syndrome ❑ Dyslipidemic triad ❑ ↑ lipoprotein ❑ ↑ clotting factors ❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2) ❑ Hyperhomocysteinemia ❑ ApoE4 isoform | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High (Framingham 10-year global risk > 20%) | Intermediate (Framingham 10-year global risk between 10% and 20%) | Lower (Framingham 10-year global risk < 10%) | Optimal (Framingham 10-year global risk < 10% with optimal levels or risk factors and heart-healthy lifestyle) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have type 2 diabetes mellitus? | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient have ALL the following criteria for low-risk dyslipidemia during previous work-up? ❑ Low LDL-C < 100 mg/dL, AND ❑ HDL-C > 50 mg/dL, AND | Adult patient | Pediatric patient (age at least 2 years) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes. The patient has ALL of the criteria for low-risk dyslipidemia | Either unknown history of lipid profile or No, the patient does not have ALL of the criteria for low-risk dyslipidemia (at least 1 criterion is not met) | Does that patient have risk factors for CAD (listed above)? | Does the patient have risk factors for CAD (listed above)? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen every 2 years | Screen annually | No | Yes | Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen patient more frequently than patients with no risk factors based on clinical judgement (unknown optimal interval) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Male patient | Female patient | Screen every 3 to 5 years | Do not screen patient for dyslipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Age between 20 and 45 years | Age > 45 years to 65 years | Age > 65 years | Age between 20 years and 55 years | Age > 55 years to 65 years | Age > 65 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen every 5 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen every 1 to 2 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen annually | Screen every 5 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen every 1 to 2 years More frequent screening is recommended for patients with risk factors for CAD (shown above) | Screen annually | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
==Complete Diagnostic Approach==
Boxes in red signify that an urgent management is needed.
Abbreviations: ASA: American society of anesthesiologists; BP: Blood Pressure; CCS: Canadian cardiovascular society; CrCl: Creatinine clearance; CXR: Chest X-ray; DNI: Do not intubate; DNR: Do not resuscitate; ECG: Electrocardiogram; eGFR: estimated glomerular filtration rate; HR:Heart rate; INR: International normalized ratio; LMWH: Low molecular weight heparin; LV: Left ventricle; LVED: Left ventricular ejection fraction; NOAC: Novel oral anticoagulant; NPO: Nothing per os; PMI: Point of maximal impulse; PT: Prothrombin time; RR: Respiratory rate; SpO2: Oxygen saturation; T: Temperature; VT: Ventricular tachycardia
Obtain a detailed history History of present illness ❑ Address specific patient symptoms and complaints ❑ Obtain review of systems relevant to dyslipidemia and diseases associated with dyslipidemia
❑ Intake of dietary fat, saturated fat, fiber, and cholesterol intake ❑ Exercise patterns ❑ History of alcohol use ❑ History of smoking ❑ History of CAD or myocardial infarction ❑ History of diabetes mellitus ❑ History of hypertension ❑ History of renal disease ❑ History of hepatic disease ❑ History of stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) ❑ History of hypothyroidism Medications ❑ Current prescribed medications ❑ List of over-the-counter drugs ❑ Previous intake of medications and reason for discontinuation ❑ History of drug adverse effects ❑ History of herbs and supplement use ❑ Compliance to medications Allergies ❑ Known drug allergies ❑ Known environmental/food allergies ❑ Family history of premature CAD (i.e. Established CAD in father or 1st degree male relative before the age of 55 years OR established CAD in mother or 1st degree female relative before the age of 65 years) ❑ Family history of hypothyroidism ❑ Family history of stroke/TIA ❑ Family history of peripheral vascular disease ❑ Occupation ❑ Exercise ❑ Diet (general) ❑ Smoking history ❑ Alcohol use ❑ Recreational drug use ❑ Stress | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assess for CAD risk factors Major risk factors: ❑ Advanced age ❑ ↑ total serum cholesterol ❑ ↑ non-HDL-C (calculated by: total cholesterol minus HDL-C) ❑ ↑ LDL-C (either measured or calculated by: total cholesterol minus HDL-c minus (total triglycerides/5)) ❑ ↓ HDL-C ❑ Diabetes mellitus ❑ Hypertension ❑ Cigarette smoking ❑ Family history of CAD ❑ Obesity, especially abdominal ❑ Family history of hyperlipidemia ❑ Small, dense LDL-C ❑ ↑ Apo-B ❑ ↑ LDL particle number (measured by ApoB) ❑ Fasting/postprandial hypertriglyceridemia ❑ Polycystic ovarian syndrome ❑ Dyslipidemic triad ❑ ↑ lipoprotein ❑ ↑ clotting factors ❑ Inflamamtory markers (e.g. hsCRP or Lipoprotein-associated phospholipase A2 (Lp-PLA2) ❑ Hyperhomocysteinemia ❑ ApoE4 isoform | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screen for possible common causes of secondary dyslipidemia Hypothyroidism: Order TSH, FT4, and FT3 Nephrosis: Order serum creatinine and urinalysis with either spot urine for proteins or 24-hour urinary collection for proteins, urinary protein to creatinine ratio Dysgammaglobulinemia: Order ANA, anti-dsDNA antibodies, plasma and urine electrophoresis Cholestatic hepatic diseases: Order GGT, ALP, and bilirubins Chronic kidney disease: Order serum creatinine, BUN, urinalysis, and renal ultrasound Type 2 diabetes mellitus: Order glycemia and HbA1c Excessive alcohol intake Drugs (estrogen, progestin, protease inhibitors, beta-blockers, corticosteroids, anabolic steroids) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaluate the patient's 10-year global risk of CAD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order tests to rule out secondary causes of dyslipidemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order fasting lipid profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total cholesterol | LDL-C | HDL-C | Triglycerides | Non HDL-C | Additional tests | ||||||||||||||||||||||||||||||||||||||||||||||||||||